medcelerator · clinician one-pager
New Treatment for a Rare Blood Cancer (BPDCN) in Adults
Decnupaz (pivekimab sunirine-pvzy) — CD123 ADC for adults with BPDCN
FDA Approved · United States · September 11, 2026
Condition: Blastic Plasmacytoid Dendritic Cell Neoplasm
Who this is for
This is for adults with BPDCN — an ultra-rare, aggressive blood/bone-marrow cancer that often involves skin, marrow, nodes, and other organs — who may be candidates for labelled US Decnupaz. It explains the FDA label, CADENZA complete-remission numbers in newly diagnosed and relapsed/refractory disease, the VOD and infusion-reaction watchpoints, how the every-3-week IV schedule and premeds work, and how to talk with a hematology clinician — without treating a foreign trial site or a DIY import as the care plan. Authorized is not funded.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/761460Orig1s000ltr.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/decnupaz-pivekimab-sunirine